688809-04-3Relevant articles and documents
Structure-based drug design of a highly potent CDK1,2,4,6 inhibitor with novel macrocyclic quinoxalin-2-one structure
Kawanishi, Nobuhiko,Sugimoto, Tetsuya,Shibata, Jun,Nakamura, Kaori,Masutani, Kouta,Ikuta, Mari,Hirai, Hiroshi
, p. 5122 - 5126 (2007/10/03)
The design of a novel series of cyclin-dependent kinase (CDK) inhibitors containing a macrocyclic quinoxaline-2-one is reported. Structure-based drug design and optimization from the starting point of diarylurea 2, which we previously reported as a modera
NOVEL QUINOXALINE DERIVATIVES
-
Page/Page column 125-126, (2008/06/13)
A quinoxalinone derivative of the formula (I): or a pharmaceutically acceptable salt or ester thereof, wherein; ???X is NH, S or the like; ???Y is O or the like; ???the partial structure is, for example, the formula: ???B1, B2, ....., Bn-1 and Bn, (in which n is 4 , 5 or 6) are each independently CH, N or the like; ???B'1, B'2, ....., B'n-1 and B'n (in which n is 4, 5 or 6) are each independently hydrogen or the like; and ???R is hydrogen, lower alkyl or the like.